437 related articles for article (PubMed ID: 31251339)
1. Studying Parkinson's disease using Caenorhabditis elegans models in microfluidic devices.
Youssef K; Tandon A; Rezai P
Integr Biol (Camb); 2019 May; 11(5):186-207. PubMed ID: 31251339
[TBL] [Abstract][Full Text] [Related]
2. Modeling Parkinson's Disease in C. elegans.
Cooper JF; Van Raamsdonk JM
J Parkinsons Dis; 2018; 8(1):17-32. PubMed ID: 29480229
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective Effects of Betulin in Pharmacological and Transgenic Caenorhabditis elegans Models of Parkinson's Disease.
Tsai CW; Tsai RT; Liu SP; Chen CS; Tsai MC; Chien SH; Hung HS; Lin SZ; Shyu WC; Fu RH
Cell Transplant; 2017 Dec; 26(12):1903-1918. PubMed ID: 29390878
[TBL] [Abstract][Full Text] [Related]
4. Holothuria scabra extracts exhibit anti-Parkinson potential in C. elegans: A model for anti-Parkinson testing.
Chalorak P; Jattujan P; Nobsathian S; Poomtong T; Sobhon P; Meemon K
Nutr Neurosci; 2018 Jul; 21(6):427-438. PubMed ID: 28276260
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease.
Harrington AJ; Yacoubian TA; Slone SR; Caldwell KA; Caldwell GA
J Neurosci; 2012 Feb; 32(6):2142-53. PubMed ID: 22323726
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in
Martinez BA; Petersen DA; Gaeta AL; Stanley SP; Caldwell GA; Caldwell KA
J Neurosci; 2017 Nov; 37(46):11085-11100. PubMed ID: 29030433
[TBL] [Abstract][Full Text] [Related]
7. n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.
Fu RH; Harn HJ; Liu SP; Chen CS; Chang WL; Chen YM; Huang JE; Li RJ; Tsai SY; Hung HS; Shyu WC; Lin SZ; Wang YC
PLoS One; 2014; 9(1):e85305. PubMed ID: 24416384
[TBL] [Abstract][Full Text] [Related]
8. Osmotic stress induced toxicity exacerbates Parkinson's associated effects via dysregulation of autophagy in transgenic C. elegans model.
Jadiya P; Mir SS; Nazir A
Cell Signal; 2018 May; 45():71-80. PubMed ID: 29410282
[TBL] [Abstract][Full Text] [Related]
9. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
10. 2-Butoxytetrahydrofuran, Isolated from
Promtang S; Sanguanphun T; Chalorak P; Pe LS; Niamnont N; Sobhon P; Meemon K
ACS Chem Neurosci; 2024 Jun; 15(11):2182-2197. PubMed ID: 38726817
[TBL] [Abstract][Full Text] [Related]
11. Anti-Parkinsonian effects of β-amyrin are regulated via LGG-1 involved autophagy pathway in Caenorhabditis elegans.
Wei CC; Chang CH; Liao VH
Phytomedicine; 2017 Dec; 36():118-125. PubMed ID: 29157804
[TBL] [Abstract][Full Text] [Related]
12. Carpesii fructus extract exhibits neuroprotective effects in cellular and Caenorhabditis elegans models of Parkinson's disease.
Zhu FD; Wang BD; Qin DL; Su XH; Yu L; Wu JM; Law BY; Guo MS; Yu CL; Zhou XG; Wu AG
CNS Neurosci Ther; 2024 Apr; 30(4):e14515. PubMed ID: 37905594
[TBL] [Abstract][Full Text] [Related]
13. α-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.
Cooper JF; Spielbauer KK; Senchuk MM; Nadarajan S; Colaiácovo MP; Van Raamsdonk JM
Exp Neurol; 2018 Dec; 310():58-69. PubMed ID: 30194957
[TBL] [Abstract][Full Text] [Related]
14. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease.
Jadiya P; Khan A; Sammi SR; Kaur S; Mir SS; Nazir A
Biochem Biophys Res Commun; 2011 Oct; 413(4):605-10. PubMed ID: 21925152
[TBL] [Abstract][Full Text] [Related]
15. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
Javed H; Kamal MA; Ojha S
CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
[TBL] [Abstract][Full Text] [Related]
16. Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.
Calahorro F; Ruiz-Rubio M
Invert Neurosci; 2011 Dec; 11(2):73-83. PubMed ID: 22068627
[TBL] [Abstract][Full Text] [Related]
17. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
18. NCEH-1 modulates cholesterol metabolism and protects against α-synuclein toxicity in a C. elegans model of Parkinson's disease.
Zhang S; Glukhova SA; Caldwell KA; Caldwell GA
Hum Mol Genet; 2017 Oct; 26(19):3823-3836. PubMed ID: 28934392
[TBL] [Abstract][Full Text] [Related]
19. Application of a C. elegans dopamine neuron degeneration assay for the validation of potential Parkinson's disease genes.
Berkowitz LA; Hamamichi S; Knight AL; Harrington AJ; Caldwell GA; Caldwell KA
J Vis Exp; 2008 Jul; (17):. PubMed ID: 19066512
[TBL] [Abstract][Full Text] [Related]
20. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans.
Kuwahara T; Koyama A; Gengyo-Ando K; Masuda M; Kowa H; Tsunoda M; Mitani S; Iwatsubo T
J Biol Chem; 2006 Jan; 281(1):334-40. PubMed ID: 16260788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
